The BOLERO-2 trial showed substantial improvements in PFS with the combination of everolimus and exemestane, compared with exemestane alone, in patients with advanced HR-positive breast cancer who had progressed on nonsteroidal aromatase inhibitors.11 Despite these improvements in PFS, resistance to the combination of everolimus and exemestane can occur. Here, CYP19A1 is linked to breast carcinoma.